Shiga Microalbuminuria Reduction Trial-2

PHASE4CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Type 2 Diabetes MellitusHypertension
Interventions
DRUG

Aliskiren

The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.

DRUG

any angiotensin receptor blockers

The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.

Trial Locations (1)

520-2192

Shiga University of Medical Science, Ōtsu

All Listed Sponsors
lead

Shiga University

OTHER

NCT01461499 - Shiga Microalbuminuria Reduction Trial-2 | Biotech Hunter | Biotech Hunter